1 4123 188 MECHANISMS OF DIMETHYLBENZANTHRACENE-INDUCED IMMUNOTOXICITY. TRADITIONAL METHODS FOR TOXICOLOGICAL ASSESSMENT HAVE IMPLICATED THE IMMUNE SYSTEM AS A FREQUENT TARGET ORGAN OF TOXIC INSULT FOLLOWING CHRONIC EXPOSURE TO CERTAIN ENVIRONMENTAL CHEMICALS, RADIATION OR THERAPEUTIC DRUGS (XENOBIOTICS). IMMUNOTOXICITY IS EXPRESSED AS AUTOIMMUNITY, CHEMICAL HYPERSENSITIVITY OR IMMUNOSUPPRESSION. A TIERED APPROACH FOR CHARACTERIZING CHEMICAL AND DRUG-INDUCED IMMUNOMODULATION HAS BEEN DEVELOPED AND VALIDATED IN LABORATORY ANIMALS. POLYCYCLIC AROMATIC HYDROCARBONS (PAH) HAVE BEEN STUDIED BECAUSE OF THEIR UBIQUITOUS PRESENCE IN THE ENVIRONMENT AND CARCINOGENIC POTENTIAL. SINCE IMMUNOSUPPRESSION INDUCED BY PAH CARCINOGENS HAS BEEN IMPLICATED AS AN EPIGENETIC MECHANISM IN THE OUTGROWTH OF INITIATED CELLS, THIS TIERED APPROACH WAS USED TO CHARACTERIZE THE MECHANISM OF PAH IMMUNOSUPPRESSIVE CAPACITY. PREVIOUSLY, STUDIES IN THIS LABORATORY HAVE DEMONSTRATED THAT SUBCHRONIC EXPOSURE OF B6C3F1 MICE TO PAH CARCINOGENS SUPPRESSES BOTH HUMORAL IMMUNITY (HI) AND CELL-MEDIATED IMMUNITY (CMI), CONCURRENTLY WITH DECREASED RESISTANCE TO TUMOR CHALLENGE. THE POTENT CARCINOGENIC PAH, 7,12-DIMETHYLBENZ[A]ANTHRACENE (DMBA) WAS SUBCHRONICALLY ADMINISTERED SUBCUTANEOUSLY AT 5, 50, OR 100 MICROGRAMS/G OF BODY WEIGHT. NATURAL KILLER (NK) CELL TUMOR CYTOLYSIS, GENERATION OF CYTOTOXIC T-CELLS (CTL), AND LYMPHOPROLIFERATION TO MITOGENS AND ALLOGENEIC SPLENOCYTES IN MIXED LEUKOCYTE CULTURES (MLC) WERE QUANTITATED 3-5 DAYS AFTER EXPOSURE TO ASSESS CMI. MITOGEN AND ALLOANTIGEN-INDUCED PROLIFERATION (MLC) OF SPLENOCYTES WAS SUPPRESSED UP TO 90%. CTL AND NK TUMOR CYTOLYSIS OF RADIOLABELLED TARGET CELLS WERE SIMILARLY DEPRESSED UP TO 88 AND 82%, RESPECTIVELY. IMPAIRMENT OF MLC OR CTL RESPONSES CORRELATED WITH INCREASED SUSCEPTIBILITY TO CHALLENGE WITH PYB6 SARCOMA CELLS. HI WAS MEASURED BY QUANTITATING THE NUMBER OF ANTIBODY (IGM) PLAQUE-FORMING CELLS (PFC) PRODUCED IN RESPONSE TO T-CELL DEPENDENT ANTIGEN CHALLENGE (SHEEP ERYTHROCYTES) AND WAS SIMILARLY SUPPRESSED UP TO 95%. TO UNDERSTAND THE MECHANISM OF PAH-INDUCED IMMUNOTOXICITY, SPLENOCYTES FROM DMBA-EXPOSED MICE WERE SENSITIZED TO ALLOANTIGENS IN THE PRESENCE OF INTERLEUKIN-2 (IL-2) BECAUSE THERE WERE INDICATIONS THAT T-HELPER CELL FUNCTION WAS SUPPRESSED. IN THESE PRELIMINARY STUDIES, CTL SUPPRESSION COULD BE COMPLETELY RESTORED BY THE ADDITION OF THE T-CELL GROWTH SUPPORTING LYMPHOKINE (IL-2) DURING THE INDUCTIVE PHASE OF CTL GENERATION, SUGGESTING THAT DMBA EXPOSURE DIRECTLY OR INDIRECTLY INDUCED DEFICITS IN T-HELPER CELL FUNCTION. 1985 2 1426 28 DIFFERENTIAL EFFECTS OF BUTYRIC ACID ON MOUSE SKIN TUMORIGENESIS. WE STUDIED THE EFFECTS OF BUTYRIC ACID (BA) ON MOUSE SKIN TUMORIGENESIS USING CHRONIC ANIMAL BIOASSAYS. TOPICAL APPLICATION OF BA IMMEDIATELY AFTER EACH TREATMENT WITH 12-0-TETRADECANOYLPHORBOL-13-ACETATE (TPA) PROMOTER-INHIBITED SKIN TUMORS. THE EFFECT WAS DEPENDENT ON THE DOSE OF BA APPLIED. BA SHOWED NO MARKED INHIBITORY EFFECT ON EITHER SKIN TUMOR INITIATION OR COMPLETE TUMORIGENESIS INDUCED BY DIMETHYLBENZANTHRACENE (DMBA). SINCE TUMOR PROMOTION REPORTEDLY INVOLVES EPIGENETIC EVENTS WHEREAS TUMOR INITIATION OR COMPLETE TUMORIGENESIS TAKES PLACE THROUGH GENETIC PATHWAYS, IT IS POSSIBLE THAT BA EXERTS ITS ANTITUMORIGENIC EFFECTS MAINLY BY ALTERING THE EPIGENETIC EVENTS RESPONSIBLE FOR TUMOR PROMOTION. THE RESULTS OF THE STUDY COULD FURTHER BE USED TO STUDY THE MECHANISM OF ACTION AND MODIFICATION OF ANTITUMORIGENIC EFFECTS OF BA IN COMBINATION WITH OTHER SUBSTANCES. 1997 3 6514 24 TRANSCRIPTIONAL ACTIVATION OF THE GP91PHOX NADPH OXIDASE SUBUNIT BY TPA IN HL-60 CELLS. THE EXPOSURE TO EPIGENETIC EFFECTORS CAPABLE OF INDUCING COPIOUS PRODUCTION OF REACTIVE OXYGEN SPECIES (ROS) HAS BEEN ASSOCIATED WITH CHRONIC INFLAMMATION, TUMOR INITIATION, AND PROMOTION. THE OBJECTIVE OF THIS STUDY WAS TO EXAMINE THE REGULATION OF GP91PHOX, THE CATALYTIC SUBUNIT OF THE NADPH OXIDASE, AND THE KINETICS OF ROS PRODUCTION IN PROMYELOCYTIC LEUKEMIA HL-60 CELLS INDUCED WITH 12-O-TETRADECONYLPHORBOL-13-ACETATE (TPA). THE TREATMENT OF HL-60 CELLS WITH TPA (0.1 MICROM) INDUCED CELLULAR DIFFERENTIATION, WHICH WAS FOLLOWED AFTER 48 H BY A TENFOLD INCREASE IN CHEMILUMINESCENCE FROM LUCIGENIN AND A 2.5-FOLD INCREASE IN THE INTRACELLULAR OXIDATION OF 2',7'-DICHOLOROFLUORESCIN (DCFH). WHEREAS HIGHER CONCENTRATIONS (1.0 MICROM) OF TPA DID NOT STIMULATE FURTHER ROS PRODUCTION, REPEATED STIMULATION WITH 0.1 MICROM TPA OF DIFFERENTIATED CELLS INDUCED A MODEST (1.2-FOLD) BUT RAPID (15 MIN) INCREASE IN CHEMILUMINESCENCE. IN CELLS TREATED WITH TPA, THE BURST IN ROS AT 48 H WAS PRECEDED BY ACCUMULATION AT 12 H OF GP91PHOX (8.8-FOLD) AND P47PHOX MRNA (THREEFOLD), WHEREAS UNTREATED CELLS CONTAINED STEADY-STATE LEVELS OF BOTH TRANSCRIPTS. TIME-COURSE EXPERIMENTS WITH ACTINOMYCIN D TO INHIBIT TRANSCRIPTION REVEALED THAT TPA DID NOT IMPROVE THE STABILITY OF GP91PHOX. IN TRANSIENT TRANSFECTIONS, LUCIFERASE REPORTER ACTIVITY DIRECTED FROM A 1.5-KB GP91PHOX PROMOTER FRAGMENT WAS ENHANCED THREEFOLD UPON TREATMENT WITH TPA FOR 24 H. WE CONCLUDE THAT TPA CAN COMMIT HL-60 CELLS TO DIFFERENTIATION AND ELICIT TRANSCRIPTION FROM THE PROXIMAL GP91PHOX PROMOTER. 2001 4 5849 34 SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) AND CLADRIBINE SYNERGISTICALLY INDUCE APOPTOSIS IN NK-LGL LEUKAEMIA. NATURAL KILLER (NK) LARGE GRANULAR LYMPHOCYTE (LGL) LEUKAEMIA FEATURES A CLONAL PROLIFERATION OF CD3(-) NK CELLS THAT CAN BE CLASSIFIED INTO EITHER AGGRESSIVE OR CHRONIC CATEGORIES. THE NKL CELL LINE, DERIVED FROM AN AGGRESSIVE ASIAN NK CELL LEUKAEMIA, AND PATIENT SAMPLES FROM CHRONIC NK-LGL LEUKAEMIA WERE USED IN OUR STUDY TO PROBE FOR SYNERGISTIC EFFICACY OF THE EPIGENETIC DRUGS VORINOSTAT (SAHA) AND CLADRIBINE IN THIS DISEASE. WE DEMONSTRATE THAT HISTONE DEACETYLASES (HDACS) ARE OVER-EXPRESSED IN BOTH AGGRESSIVE AND CHRONIC NK LEUKAEMIA. ADMINISTRATION OF THE HDAC INHIBITOR SAHA REDUCES CLASS I AND II HDAC EXPRESSION AND ENHANCES HISTONE ACETYLATION IN LEUKAEMIC NK CELLS. IN VITRO COMBINATION TREATMENT WITH SAHA AND CLADRIBINE DOSE-DEPENDENTLY EXERTS SYNERGISTIC CYTOTOXIC AND APOPTOTIC EFFECTS ON LEUKAEMIC NK CELLS. EXPRESSION PROFILING OF APOPTOTIC REGULATORY GENES SUGGESTS THAT BOTH COMPOUNDS LED TO CASPASE-DEPENDENT APOPTOSIS THROUGH ACTIVATION OF INTRINSIC MITOCHONDRIAL AND EXTRINSIC DEATH RECEPTOR PATHWAYS. COLLECTIVELY, THESE DATA SHOW THAT COMBINED EPIGENETIC THERAPY, USING HDAC AND DNA METHYLTRANSFERASE INHIBITORS, MAY BE A PROMISING THERAPEUTIC APPROACH FOR NK-LGL LEUKAEMIA. 2015 5 5613 34 SAFETY AND EFFICACY OF ABEXINOSTAT, A PAN-HISTONE DEACETYLASE INHIBITOR, IN NON-HODGKIN LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PHASE II STUDY. HISTONE DEACETYLASE INHIBITORS ARE MEMBERS OF A CLASS OF EPIGENETIC DRUGS THAT HAVE PROVEN ACTIVITY IN T-CELL MALIGNANCIES, BUT LITTLE IS KNOWN ABOUT THEIR EFFICACY IN B-CELL LYMPHOMAS. ABEXINOSTAT IS AN ORALLY AVAILABLE HYDROXAMATE-CONTAINING HISTONE DEACETYLASE INHIBITOR THAT DIFFERS FROM APPROVED INHIBITORS; ITS UNIQUE PHARMACOKINETIC PROFILE AND ORAL DOSING SCHEDULE, TWICE DAILY FOUR HOURS APART, ALLOWS FOR CONTINUOUS EXPOSURE AT CONCENTRATIONS REQUIRED TO EFFICIENTLY KILL TUMOR CELLS. IN THIS PHASE II STUDY, PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA OR CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVED ORAL ABEXINOSTAT AT 80 MG BID FOR 14 DAYS OF A 21-DAY CYCLE AND CONTINUED UNTIL PROGRESSIVE DISEASE OR UNACCEPTABLE TOXICITY. A TOTAL OF 100 PATIENTS WITH B-CELL MALIGNANCIES AND T-CELL LYMPHOMAS WERE ENROLLED BETWEEN OCTOBER 2011 AND JULY 2014. ALL PATIENTS RECEIVED AT LEAST ONE DOSE OF STUDY DRUG. PRIMARY REASONS FOR DISCONTINUATION INCLUDED PROGRESSIVE DISEASE (56%) AND ADVERSE EVENTS (25%). GRADE 3 OR OVER ADVERSE EVENTS AND ANY SERIOUS ADVERSE EVENTS WERE REPORTED IN 88% AND 73% OF PATIENTS, RESPECTIVELY. THE MOST FREQUENTLY REPORTED GRADE 3 OR OVER TREATMENT-EMERGENT RELATED ADVERSE EVENTS WERE THROMBOCYTOPENIA (80%), NEUTROPENIA (27%), AND ANEMIA (12%). AMONG THE 87 PATIENTS EVALUABLE FOR EFFICACY, OVERALL RESPONSE RATE WAS 28% (COMPLETE RESPONSE 5%), WITH HIGHEST RESPONSES OBSERVED IN PATIENTS WITH FOLLICULAR LYMPHOMA (OVERALL RESPONSE RATE 56%), T-CELL LYMPHOMA (OVERALL RESPONSE RATE 40%), AND DIFFUSE LARGE B-CELL LYMPHOMA (OVERALL RESPONSE RATE 31%). FURTHER INVESTIGATION OF THE SAFETY AND EFFICACY OF ABEXINOSTAT IN FOLLICULAR LYMPHOMA, T-CELL LYMPHOMA, AND DIFFUSE LARGE B-CELL LYMPHOMA IMPLEMENTING A LESS DOSE-INTENSE WEEK-ON-WEEK-OFF SCHEDULE IS WARRANTED. (TRIAL REGISTERED AT: EUDRACT-2009-013691-47). 2017 6 5617 33 SARCOSINE SUPPRESSES EPILEPTOGENESIS IN RATS WITH EFFECTS ON HIPPOCAMPAL DNA METHYLATION. EPILEPTOGENESIS IS A COMMON CONSEQUENCE OF BRAIN INSULTS, HOWEVER, THE PREVENTION OR DELAY OF THE EPILEPTOGENIC PROCESS REMAINS AN IMPORTANT UNMET MEDICAL CHALLENGE. OVEREXPRESSION OF GLYCINE TRANSPORTER 1 (GLYT1) IS PROPOSED AS A PATHOLOGICAL HALLMARK IN THE HIPPOCAMPUS OF PATIENTS WITH TEMPORAL LOBE EPILEPSY (TLE), AND WE PREVIOUSLY DEMONSTRATED IN RODENT EPILEPSY MODELS THAT AUGMENTATION OF GLYCINE SUPPRESSED CHRONIC SEIZURES AND ALTERED ACUTE SEIZURE THRESHOLDS. IN THE PRESENT STUDY WE EVALUATED THE EFFECT OF THE GLYT1 INHIBITOR, SARCOSINE (AKA N-METHYLGLYCINE), ON EPILEPTOGENESIS AND ALSO INVESTIGATED POSSIBLE MECHANISMS. WE DEVELOPED A MODIFIED RAPID KINDLING MODEL OF EPILEPTOGENESIS IN RATS COMBINED WITH SEIZURE SCORE MONITORING TO EVALUATE THE ANTIEPILEPTOGENIC EFFECT OF SARCOSINE. WE USED IMMUNOHISTOCHEMISTRY AND WESTERN BLOT ANALYSIS FOR THE EVALUATION OF GLYT1 EXPRESSION AND EPIGENETIC CHANGES OF 5-METHYLCYTOSINE (5MC) AND 5-HYDROXYMETHYLCYTOSINE (5HMC) IN THE EPILEPTOGENIC HIPPOCAMPI OF RATS, AND FURTHER EVALUATED EXPRESSION CHANGES IN ENZYMES INVOLVED IN THE REGULATION OF DNA METHYLATION, TEN-ELEVEN TRANSLOCATION METHYLCYTOSINE DIOXYGENASE 1 (TET1), DNA-METHYLTRANSFERASE 1 (DNMT1), AND DNMT3A. OUR RESULTS DEMONSTRATED: (I) EXPERIMENTAL EVIDENCE THAT SARCOSINE (3 G/KG, I.P. DAILY) SUPPRESSED KINDLING EPILEPTOGENESIS IN RATS; (II) THE SARCOSINE-INDUCED ANTIEPILEPTOGENIC EFFECT WAS ACCOMPANIED BY A SUPPRESSED HIPPOCAMPAL GLYT1 EXPRESSION AS WELL AS A REDUCTION OF HIPPOCAMPAL 5MC LEVELS AND A CORRESPONDING INCREASE IN 5HMC; AND (III) SARCOSINE TREATMENT CAUSED DIFFERENTIAL EXPRESSION CHANGES OF TET1 AND DNMTS. TOGETHER, THESE FINDINGS SUGGEST THAT SARCOSINE HAS UNPRECEDENTED DISEASE-MODIFYING PROPERTIES IN A KINDLING MODEL OF EPILEPTOGENESIS IN RATS, WHICH WAS ASSOCIATED WITH ALTERED HIPPOCAMPAL DNA METHYLATION. THUS, MANIPULATION OF THE GLYCINE SYSTEM IS A POTENTIAL THERAPEUTIC APPROACH TO ATTENUATE THE DEVELOPMENT OF EPILEPSY. 2020 7 5902 43 T-HELPER 17 CELL POLARIZATION IN PULMONARY ARTERIAL HYPERTENSION. BACKGROUND: INFLAMMATION MAY CONTRIBUTE TO THE PATHOBIOLOGY OF PULMONARY ARTERIAL HYPERTENSION (PAH). DECIPHERING THE PAH FINGERPRINT ON THE INFLAMMATION ORCHESTRATED BY DENDRITIC CELLS (DCS) AND T CELLS, KEY DRIVER AND EFFECTOR CELLS, RESPECTIVELY, OF THE IMMUNE SYSTEM, MAY ALLOW THE IDENTIFICATION OF IMMUNOPATHOLOGIC APPROACHES TO PAH MANAGEMENT. METHODS: USING FLOW CYTOMETRY, WE PERFORMED IMMUNOPHENOTYPING OF MONOCYTE-DERIVED DCS (MODCS) AND CIRCULATING LYMPHOCYTES FROM PATIENTS WITH IDIOPATHIC PAH AND CONTROL SUBJECTS. WITH THE SAME TECHNIQUE, WE PERFORMED CYTOKINE PROFILING OF BOTH POPULATIONS FOLLOWING STIMULATION, COCULTURE, OR BOTH. WE TESTED THE IMMUNOMODULATORY EFFECTS OF A GLUCOCORTICOID (DEXAMETHASONE [DEX]) ON THIS IMMUNOPHENOTYPE AND CYTOKINE PROFILE. USING AN EPIGENETIC APPROACH, WE CONFIRMED THE IMMUNE POLARIZATION IN BLOOD DNA OF PATIENTS WITH PAH. RESULTS: THE PROFILE OF MEMBRANE COSTIMULATORY MOLECULES OF PAH MODCS WAS SIMILAR TO THAT OF CONTROL SUBJECTS. HOWEVER, PAH MODCS RETAINED HIGHER LEVELS OF THE T-CELL ACTIVATING MOLECULES CD86 AND CD40 AFTER DEX PRETREATMENT THAN DID CONTROL MODCS. THIS WAS ASSOCIATED WITH AN INCREASED EXPRESSION OF IL-12P40 AND A REDUCED MIGRATION TOWARD CHEMOKINE (C-C MOTIF) LIGAND 21. MOREOVER, BOTH WITH AND WITHOUT DEX, PAH MODCS INDUCED A HIGHER ACTIVATION AND PROLIFERATION OF CD4+ T CELLS, ASSOCIATED WITH A REDUCED EXPRESSION OF IL-4 (T HELPER 2 RESPONSE) AND A HIGHER EXPRESSION OF IL-17 (T HELPER 17 RESPONSE). PURIFIED PAH CD4+ T CELLS EXPRESSED A HIGHER LEVEL OF IL-17 AFTER ACTIVATION THAN DID THOSE OF CONTROL SUBJECTS. LASTLY, THERE WAS SIGNIFICANT HYPOMETHYLATION OF THE IL-17 PROMOTER IN THE PAH BLOOD DNA AS COMPARED WITH THE CONTROL BLOOD. CONCLUSIONS: WE HAVE HIGHLIGHTED T HELPER 17 CELL IMMUNE POLARIZATION IN PATIENTS WITH PAH, AS HAS BEEN PREVIOUSLY DEMONSTRATED IN OTHER CHRONIC INFLAMMATORY AND AUTOIMMUNE CONDITIONS. 2015 8 5187 32 PRENATAL AIRBORNE POLYCYCLIC AROMATIC HYDROCARBON EXPOSURE, ALTERED REGULATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPAR)GAMMA, AND LINKS WITH MAMMARY CANCER. ENVIRONMENTAL EXPOSURE TO POLYCYCLIC AROMATIC HYDROCARBONS (PAH) HAS BEEN SHOWN TO BE ASSOCIATED WITH CHRONIC DISEASE OUTCOMES THROUGH MULTIPLE MECHANISMS INCLUDING ALTERED REGULATION OF THE TRANSCRIPTION FACTOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPAR) GAMMA. BECAUSE PAH EXPOSURE AND PPARGAMMA EACH HAVE BEEN ASSOCIATED WITH MAMMARY CANCER, WE ASKED WHETHER PAH WOULD INDUCE ALTERED REGULATION OF PPARGAMMA IN MAMMARY TISSUE, AND WHETHER THIS ASSOCIATION MAY UNDERLIE THE ASSOCIATION BETWEEN PAH AND MAMMARY CANCER. PREGNANT MICE WERE EXPOSED TO AEROSOLIZED PAH AT PROPORTIONS THAT MIMIC EQUIVALENT HUMAN EXPOSURES IN NEW YORK CITY AIR. WE HYPOTHESIZED THAT PRENATAL PAH EXPOSURE WOULD ALTER PPARGAMMA DNA METHYLATION AND GENE EXPRESSION AND INDUCE THE EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) IN MAMMARY TISSUE OF OFFSPRING (F1) AND GRANDOFFSPRING (F2) MICE. WE ALSO HYPOTHESIZED THAT ALTERED REGULATION OF PPARGAMMA IN MAMMARY TISSUE WOULD ASSOCIATE WITH BIOMARKERS OF EMT, AND EXAMINED ASSOCIATIONS WITH WHOLE BODY WEIGHT. WE FOUND THAT PRENATAL PAH EXPOSURE LOWERED PPARGAMMA MAMMARY TISSUE METHYLATION AMONG GRANDOFFSPRING MICE AT POSTNATAL DAY (PND) 28. HOWEVER, PAH EXPOSURE DID NOT ASSOCIATE WITH ALTERED PPARGAMMA GENE EXPRESSION OR CONSISTENTLY WITH BIOMARKERS OF EMT. FINALLY, LOWER PPARGAMMA METHYLATION, BUT NOT GENE EXPRESSION, WAS ASSOCIATED WITH HIGHER BODY WEIGHT AMONG OFFSPRING AND GRANDOFFSPRING MICE AT PND28 AND PND60. FINDINGS SUGGEST ADDITIONAL EVIDENCE OF MULTI-GENERATIONAL ADVERSE EPIGENETIC EFFECTS OF PRENATAL PAH EXPOSURE AMONG GRANDOFFSPRING MICE. 2023 9 6614 40 ULTRAVIOLET IRRADIATION INDUCES KERATINOCYTE PROLIFERATION AND EPIDERMAL HYPERPLASIA THROUGH THE ACTIVATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR. CHRONIC EXPOSURE TO ULTRAVIOLET (UV) IRRADIATION INDUCES SKIN CANCER, IN PART, THROUGH EPIGENETIC MECHANISMS THAT RESULT IN THE DEREGULATION OF CELL PROLIFERATION. UV IRRADIATION ALSO RAPIDLY ACTIVATES THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR). SINCE EGFR ACTIVATION IS STRONGLY MITOGENIC IN MANY CELL TYPES INCLUDING KERATINOCYTES OF THE SKIN, WE HYPOTHESIZED THAT UV-INDUCED CUTANEOUS PROLIFERATION RESULTS FROM EGFR ACTIVATION. THE ROLE OF EGFR ACTIVATION IN THE RESPONSE OF THE SKIN TO UV WAS DETERMINED USING EGFR-NULL AND EGFR-WILD-TYPE SKIN GRAFTED ONTO ATHYMIC NUDE MOUSE HOSTS, BECAUSE EGFR-NULL MICE SURVIVE ONLY A FEW DAYS AFTER BIRTH. EGFR WAS RAPIDLY ACTIVATED IN MOUSE EPIDERMIS FOLLOWING EXPOSURE TO UV, AS DETECTED BY THE PHOSPHORYLATION OF EGFR ON TYROSINE RESIDUES 992, 1045, 1068 AND 1173. UV INDUCED EPIDERMAL HYPERPLASIA IN EGFR-WILD-TYPE SKIN BETWEEN 48 AND 72 H POST-UV. HOWEVER, NO EPIDERMAL HYPERPLASIA OCCURRED IN EGFR-NULL SKIN. BASELINE CELL PROLIFERATION WAS SIMILAR IN SKIN GRAFTS OF BOTH GENOTYPES. HOWEVER, UV EXPOSURE INCREASED CELL PROLIFERATION, AS MEASURED BY KI67 IMMUNOHISTOCHEMISTRY AND PROLIFERATING CELL NUCLEAR ANTIGEN IMMUNOBLOTTING, MAXIMALLY AT 48 H TO A LEVEL MORE THAN THREE TIMES HIGHER IN WILD-TYPE COMPARED WITH EGFR-NULL SKIN. APOPTOTIC CELL DEATH, AS MEASURED BY TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE BIOTIN-DUTP NICK END LABELING (TUNEL) ANALYSIS, WAS ALSO INCREASED IN UV-EXPOSED EGFR-NULL SKIN WHEN COMPARED WITH WILD-TYPE 1-2 DAYS POST-UV. THESE CHANGES IN CELLULAR HOMEOSTASIS AFTER UV WERE ACCOMPANIED BY INCREASED CYCLIN D EXPRESSION IN WILD-TYPE BUT NOT EGFR-NULL SKIN AND INCREASED EXPRESSION OF P53 AND THE CYCLIN-DEPENDENT KINASE (CDK) INHIBITOR P21WAF1 IN EGFR-NULL SKIN WHEN COMPARED WITH WILD-TYPE. COLLECTIVELY, THESE RESULTS DEMONSTRATE THAT THE UV-INDUCED ACTIVATION OF EGFR AUGMENTS KERATINOCYTE PROLIFERATION AND SUPPRESSES APOPTOSIS, LEADING TO EPIDERMAL HYPERPLASIA, ASSOCIATED WITH INCREASED G1 CYCLIN EXPRESSION AND SUPPRESSION OF CDK INHIBITOR EXPRESSION. 2006 10 3175 38 H2AX PHOSPHORYLATION REGULATED BY P38 IS INVOLVED IN BIM EXPRESSION AND APOPTOSIS IN CHRONIC MYELOGENOUS LEUKEMIA CELLS INDUCED BY IMATINIB. INCREASING EVIDENCE SUGGESTS THAT HISTONE H2AX PLAYS A CRITICAL ROLE IN REGULATION OF TUMOR CELL APOPTOSIS AND ACTS AS A NOVEL HUMAN TUMOR SUPPRESSOR PROTEIN. HOWEVER, THE ACTION OF H2AX IN CHRONIC MYELOGENOUS LEUKEMIA (CML) CELLS IS UNKNOWN. THE DETAILED MECHANISM AND EPIGENETIC REGULATION BY H2AX REMAIN ELUSIVE IN CANCER CELLS. HERE, WE REPORT THAT H2AX WAS INVOLVED IN APOPTOSIS OF CML CELLS. OVEREXPRESSION OF H2AX INCREASED APOPTOTIC SENSITIVITY OF CML CELLS (K562) INDUCED BY IMATINIB. HOWEVER, OVEREXPRESSION OF SER139-MUTATED H2AX (BLOCKING PHOSPHORYLATION) DECREASED SENSITIVITY OF K562 CELLS TO APOPTOSIS. SIMILARLY, KNOCKDOWN OF H2AX MADE K562 CELLS RESISTANT TO APOPTOTIC INDUCTION. THESE RESULTS REVEALED THAT THE FUNCTION OF H2AX INVOLVED IN APOPTOSIS IS STRICTLY RELATED TO ITS PHOSPHORYLATION (SER139). OUR DATA FURTHER INDICATED THAT IMATINIB MAY STIMULATE MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) FAMILY MEMBER P38, AND H2AX PHOSPHORYLATION FOLLOWED A SIMILAR TIME COURSE, SUGGESTING A PARALLEL RESPONSE. H2AX PHOSPHORYLATION CAN BE BLOCKED BY P38 SIRNA OR ITS INHIBITOR. THESE DATA DEMONSTRATED THAT H2AX PHOSPHORYLATION WAS REGULATED BY P38 MAPK PATHWAY IN K562 CELLS. HOWEVER, THE P38 MAPK DOWNSTREAM, MITOGEN- AND STRESS-ACTIVATED PROTEIN KINASE-1 AND -2, WHICH PHOSPHORYLATED HISTONE H3, WERE NOT REQUIRED FOR H2AX PHOSPHORYLATION DURING APOPTOSIS. FINALLY, WE PROVIDED EPIGENETIC EVIDENCE THAT H2AX PHOSPHORYLATION REGULATED APOPTOSIS-RELATED GENE BIM EXPRESSION. BLOCKING OF H2AX PHOSPHORYLATION INHIBITED BIM GENE EXPRESSION. TAKEN TOGETHER, THESE DATA DEMONSTRATED THAT H2AX PHOSPHORYLATION REGULATED BY P38 IS INVOLVED IN BIM EXPRESSION AND APOPTOSIS IN CML CELLS INDUCED BY IMATINIB. 2014 11 5478 30 RESULTS OF A RANDOMIZED STUDY OF 3 SCHEDULES OF LOW-DOSE DECITABINE IN HIGHER-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA. EPIGENETIC THERAPY WITH HYPOMETHYLATING DRUGS IS NOW THE STANDARD OF CARE IN MYELODYSPLASTIC SYNDROME (MDS). RESPONSE RATES REMAIN LOW, AND MECHANISM-BASED DOSE OPTIMIZATION HAS NOT BEEN REPORTED. WE INVESTIGATED THE CLINICAL AND PHARMACODYNAMIC RESULTS OF DIFFERENT DOSE SCHEDULES OF DECITABINE. ADULTS WITH ADVANCED MDS OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) WERE RANDOMIZED TO 1 OF 3 DECITABINE SCHEDULES: (1) 20 MG/M2 INTRAVENOUSLY DAILY FOR 5 DAYS; (2) 20 MG/M2 SUBCUTANEOUSLY DAILY FOR 5 DAYS; AND (3) 10 MG/M2 INTRAVENOUSLY DAILY FOR 10 DAYS. RANDOMIZATION FOLLOWED A BAYESIAN ADAPTIVE DESIGN. NINETY-FIVE PATIENTS WERE TREATED (77 WITH MDS, AND 18 WITH CMML). OVERALL, 32 PATIENTS (34%) ACHIEVED A COMPLETE RESPONSE (CR), AND 69 (73%) HAD AN OBJECTIVE RESPONSE BY THE NEW MODIFIED INTERNATIONAL WORKING GROUP CRITERIA. THE 5-DAY INTRAVENOUS SCHEDULE, WHICH HAD THE HIGHEST DOSE-INTENSITY, WAS SELECTED AS OPTIMAL; THE CR RATE IN THAT ARM WAS 39%, COMPARED WITH 21% IN THE 5-DAY SUBCUTANEOUS ARM AND 24% IN THE 10-DAY INTRAVENOUS ARM (P < .05). THE HIGH DOSE-INTENSITY ARM WAS ALSO SUPERIOR AT INDUCING HYPOMETHYLATION AT DAY 5 AND AT ACTIVATING P15 EXPRESSION AT DAYS 12 OR 28 AFTER THERAPY. WE CONCLUDE THAT A LOW-DOSE, DOSE-INTENSITY SCHEDULE OF DECITABINE OPTIMIZES EPIGENETIC MODULATION AND CLINICAL RESPONSES IN MDS. 2007 12 3081 35 GENOME-WIDE PROMOTER DNA METHYLATION PROFILING OF HEPATOCELLULAR CARCINOMAS ARISING EITHER SPONTANEOUSLY OR DUE TO CHRONIC EXPOSURE TO GINKGO BILOBA EXTRACT (GBE) IN B6C3F1/N MICE. EPIGENETIC MODIFICATIONS, SUCH AS DNA METHYLATION, PLAY AN IMPORTANT ROLE IN CARCINOGENESIS. IN A RECENT NTP STUDY, CHRONIC EXPOSURE OF B6C3F1/N MICE TO GINKGO BILOBA EXTRACT (GBE) RESULTED IN A HIGH INCIDENCE OF HEPATOCELLULAR CARCINOMAS (HCC). GENOME-WIDE PROMOTER METHYLATION PROFILING ON GBE-EXPOSED HCC (2000 MG/KG GROUP), SPONTANEOUS HCC (VEHICLE-CONTROL GROUP), AND AGE-MATCHED VEHICLE CONTROL LIVER WAS PERFORMED TO IDENTIFY DIFFERENTIALLY METHYLATED GENES IN GBE-EXPOSED HCC AND SPONTANEOUS HCC. DNA METHYLATION ALTERATIONS WERE CORRELATED TO THE CORRESPONDING GLOBAL GENE EXPRESSION CHANGES. COMPARED TO CONTROL LIVER, 1296 GENE PROMOTERS (719 HYPERMETHYLATED, 577 HYPOMETHYLATED) IN GBE-EXPOSED HCC AND 738 (427 HYPERMETHYLATED, 311 HYPOMETHYLATED) GENE PROMOTERS IN SPONTANEOUS HCC WERE SIGNIFICANTLY DIFFERENTIALLY METHYLATED, SUGGESTING AN IMPACT OF METHYLATION ON GBE-EXPOSED HCC. DIFFERENTIAL METHYLATION OF PROMOTER REGIONS IN RELEVANT CANCER GENES (CMYC, SPRY2, DUSP5) AND THEIR CORRESPONDING DIFFERENTIAL GENE EXPRESSION WAS VALIDATED BY QUANTITATIVE PYROSEQUENCING AND QRT-PCR, RESPECTIVELY. IN CONCLUSION, WE HAVE IDENTIFIED DIFFERENTIALLY METHYLATED PROMOTER REGIONS OF RELEVANT CANCER GENES ALTERED IN GBE-EXPOSED HCC COMPARED TO SPONTANEOUS HCC. FURTHER STUDY OF UNIQUE SETS OF DIFFERENTIALLY METHYLATED GENES IN CHEMICAL-EXPOSED MOUSE HCC COULD POTENTIALLY BE USED TO DIFFERENTIATE TREATMENT-RELATED TUMORS FROM SPONTANEOUS-TUMORS IN CANCER BIOASSAYS AND PROVIDE ADDITIONAL UNDERSTANDING OF THE UNDERLYING EPIGENETIC MECHANISMS OF CHEMICAL CARCINOGENESIS. 2019 13 1653 39 DOPAMINE TRANSPORTER KNOCKOUT RATS DISPLAY EPIGENETIC ALTERATIONS IN RESPONSE TO COCAINE EXPOSURE. (1) BACKGROUND: THERE IS AN URGENT NEED FOR EFFECTIVE TREATMENTS FOR COCAINE USE DISORDER (CUD), AND NEW PHARMACOLOGICAL APPROACHES TARGETING EPIGENETIC MECHANISMS APPEAR TO BE PROMISING OPTIONS FOR THE TREATMENT OF THIS DISEASE. DOPAMINE TRANSPORTER (DAT) TRANSGENIC RATS RECENTLY HAVE BEEN PROPOSED AS A NEW ANIMAL MODEL FOR STUDYING SUSCEPTIBILITY TO CUD. (2) METHODS: DAT TRANSGENIC RATS WERE TREATED CHRONICALLY WITH COCAINE (10 MG/KG) FOR 8 DAYS, AND THE EXPRESSION OF EPIGENETIC MODULATORS, LYSINE DEMETHYLASE 6B (KDM6B) AND BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4), WAS EXAMINED IN THE PREFRONTAL CORTEX (PFC). (3) RESULTS: WE SHOW THAT ONLY FULL KNOCKOUT (KO) OF DAT IMPACTS BASAL LEVELS OF KDM6B IN FEMALES. ADDITIONALLY, COCAINE ALTERED THE EXPRESSION OF BOTH EPIGENETIC MARKERS IN A SEX- AND GENOTYPE-DEPENDENT MANNER. IN RESPONSE TO CHRONIC COCAINE, KDM6B EXPRESSION WAS DECREASED IN MALE RATS WITH PARTIAL DAT MUTATION (HET), WHILE NO CHANGES WERE OBSERVED IN WILD-TYPE (WT) OR KO RATS. INDEED, WHILE HET MALE RATS HAVE REDUCED KDM6B AND BRD4 EXPRESSION, HET FEMALE RATS SHOWED INCREASED KDM6B AND BRD4 EXPRESSION LEVELS, HIGHLIGHTING THE IMPACT OF SEX ON EPIGENETIC MECHANISMS IN RESPONSE TO COCAINE. FINALLY, BOTH MALE AND FEMALE KO RATS SHOWED INCREASED EXPRESSION OF BRD4, BUT ONLY KO FEMALES EXHIBITED SIGNIFICANTLY INCREASED KDM6B EXPRESSION IN RESPONSE TO COCAINE. ADDITIONALLY, THE MAGNITUDE OF THESE EFFECTS WAS BIGGER IN FEMALES WHEN COMPARED TO MALES FOR BOTH EPIGENETIC ENZYMES. (4) CONCLUSIONS: THIS PRELIMINARY STUDY PROVIDES ADDITIONAL SUPPORT THAT TARGETING KDM6B AND/OR BRD4 MAY POTENTIALLY BE THERAPEUTIC IN TREATING ADDICTION-RELATED BEHAVIORS IN A SEX-DEPENDENT MANNER. 2023 14 5319 32 PTEN IS FUNDAMENTAL FOR ELIMINATION OF LEUKEMIA STEM CELLS MEDIATED BY GSK126 TARGETING EZH2 IN CHRONIC MYELOGENOUS LEUKEMIA. PURPOSE: LEUKEMIA STEM CELLS (LSCS) ARE AN IMPORTANT SOURCE OF TYROSINE KINASE INHIBITOR RESISTANCE AND DISEASE RELAPSE IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA (CML). TARGETING LSCS MAY BE AN ATTRACTIVE STRATEGY TO OVERRIDE THIS THORNY PROBLEM. GIVEN THAT EZH2 WAS OVEREXPRESSED IN PRIMARY CML CD34(+) CELLS, OUR PURPOSE IN THIS STUDY WAS TO EVALUATE THE EFFECTS OF TARGETING EZH2 ON CML LSCS AND CLARIFY ITS UNDERLYING MECHANISM.EXPERIMENTAL DESIGN: HUMAN PRIMARY CML CD34(+) CELLS AND RETROVIRALLY BCR-ABL-DRIVEN CML MOUSE MODELS WERE EMPLOYED TO EVALUATE THE EFFECTS OF SUPPRESSION OF EZH2 BY GSK126- OR EZH2-SPECIFIC SHRNA IN VITRO AND IN VIVO RECRUITMENT OF EZH2 AND H3K27ME3 ON THE PROMOTER OF TUMOR-SUPPRESSOR GENE PTEN IN CML CELLS WAS MEASURED BY CHROMATIN IMMUNOPRECIPITATION ASSAY.RESULTS: OUR RESULTS SHOWED THAT PHARMACOLOGIC INHIBITION OF EZH2 BY GSK126 NOT ONLY ELICITED APOPTOSIS AND RESTRICTED CELL GROWTH IN CML BULK LEUKEMIA CELLS, BUT ALSO DECREASED LSCS IN CML CD34(+) CELLS WHILE SPARING THOSE FROM NORMAL BONE MARROW CD34(+) CELLS. SUPPRESSION OF EZH2 BY GSK126 OR SPECIFIC SHRNA PROLONGED SURVIVAL OF CML MICE AND REDUCED THE NUMBER OF LSCS IN MICE. EZH2 KNOCKDOWN RESULTED IN ELEVATION OF PTEN AND LED TO IMPAIRED RECRUITMENT OF EZH2 AND H3K27ME3 ON THE PROMOTER OF PTEN GENE. THE EFFECT OF EZH2 KNOCKDOWN IN THE CML MICE WAS AT LEAST PARTIALLY REVERSED BY PTEN KNOCKDOWN.CONCLUSIONS: THESE FINDINGS IMPROVE THE UNDERSTANDING OF THE EPIGENETIC REGULATION OF STEMNESS IN CML LSCS AND WARRANT CLINICAL TRIAL OF GSK126 IN REFRACTORY PATIENTS WITH CML. CLIN CANCER RES; 24(1); 145-57. (C)2017 AACR. 2018 15 1001 42 CHRONIC TCDD EXPOSURE RESULTS IN THE DYSREGULATION OF GENE EXPRESSION IN SPLENIC B-LYMPHOCYTES AND IN THE IMPAIRMENTS IN T-CELL AND B-CELL DIFFERENTIATION IN MOUSE MODEL. 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN (TCDD) EXPOSURE IN HUMANS IS ASSOCIATED WITH MARKED IMMUNE SUPPRESSIONS AND INCREASED INCIDENCE OF LYMPHOBLASTIC DISEASES. TO ELUCIDATE MECHANISMS OF IMPAIRMENTS IN HUMORAL IMMUNE RESPONSES, WE USED A MURINE MODEL. FOLLOWING A 20-WEEK ADMINISTRATION OF LOW DOSES OF TCDD, WE OBSERVED SEVERELY REDUCED ANTIBODY TITERS, DRAMATICALLY DECREASED NUMBER OF SPLENIC TH1 AND TH2 CELLS AND AN INCREASE IN CD19(+) B CELLS. TRANSCRIPTIONAL PROFILING OF CD19(+) B CELLS SHOWED THAT MARKERS OF PRE-B CELLS WERE SIGNIFICANTLY ELEVATED, INDICATING DELAYED B CELL MATURATION. THESE CHANGES IN B CELLS WERE ACCOMPANIED BY DECREASES OF T HELPER CELL NUMBERS AND REDUCED IGM AND IGG TITERS. A TRANSCRIPTOME ANALYSIS OF SPLENIC B CELLS FOLLOWED BY INGENUITY PATHWAY ANALYSIS (IPA) REVEALED A SET OF DIFFERENTIALLY EXPRESSED GENES KNOWN TO PLAY ROLES IN TUMORIGENESIS, CELL-PROLIFERATION AND CELL-MIGRATION. THE MOST UP-REGULATED TRANSCRIPT GENE WAS EPH RECEPTOR A2 (EPHA2), A KNOWN ONCOGENE, AND THE MOST DOWN-REGULATED TRANSCRIPT WAS ZBTB16 THAT CODES FOR A NEGATIVE TRANSCRIPTIONAL REGULATOR IMPORTANT IN EPIGENETIC CHROMATIN REMODELING. IPA IDENTIFIED CAMP-RESPONSIVE ELEMENT MODULATOR (CREM) AND CAMP-RESPONSIVE ELEMENT BINDING PROTEIN 1 (CREB1) AS TOP UPSTREAM REGULATORS. CONSISTENTLY, A MAPPER PROMOTER DATABASE ANALYSIS SHOWED THAT ALL TOP DYSREGULATED GENES HAD CREM AND/OR CREB1 BINDING SITES IN THEIR PROMOTER REGIONS. IN SUMMARY, OUR DATA SHOWED THAT CHRONIC TCDD EXPOSURE IN MICE CAUSED SUPPRESSED HUMORAL IMMUNITY ACCOMPANIED WITH PROFOUND DYSREGULATION OF GENE EXPRESSION IN SPLENIC B-LYMPHOCYTES, LIKELY THROUGH CAMP-DEPENDENT PATHWAYS. THIS DYSREGULATION RESULTED IN IMPAIRMENTS IN T-CELL AND B-CELL DIFFERENTIATION AND ACTIVATION OF THE TUMORIGENIC TRANSCRIPTION PROGRAM. 2016 16 3623 52 IN VIVO COMET ASSAY ON ISOLATED KIDNEY CELLS TO DISTINGUISH GENOTOXIC CARCINOGENS FROM EPIGENETIC CARCINOGENS OR CYTOTOXIC COMPOUNDS. THE OBJECTIVE OF THIS STUDY WAS TO DETERMINE THE ABILITY OF THE ALKALINE IN VIVO COMET ASSAY (PH>13) TO DISTINGUISH GENOTOXIC CARCINOGENS FROM EPIGENETIC CARCINOGENS WHEN PERFORMED ON FRESHLY ISOLATED KIDNEY CELLS AND TO DETERMINE THE POSSIBLE INTERFERENCE OF CYTOTOXICITY BY ASSESSING DNA DAMAGE INDUCED BY RENAL GENOTOXIC, EPIGENETIC OR TOXIC COMPOUNDS AFTER ENZYMATIC ISOLATION OF KIDNEY CELLS FROM OFA SPRAGUE-DAWLEY MALE RATS. THE ABILITY OF THE COMET ASSAY TO DISTINGUISH (1) GENOTOXICITY VERSUS CYTOTOXICITY AND (2) GENOTOXIC VERSUS NON-GENOTOXIC (EPIGENETIC) CARCINOGENS, WAS THUS INVESTIGATED BY STUDYING FIVE KNOWN GENOTOXIC RENAL CARCINOGENS ACTING THROUGH DIVERSE MECHANISMS OF ACTION, I.E. STREPTOZOTOCIN, ARISTOLOCHIC ACIDS, 2-NITROANISOLE, POTASSIUM BROMATE AND CISPLATIN, TWO RODENT RENAL EPIGENETIC CARCINOGENS: D-LIMONENE AND CICLOSPORINE AND TWO NEPHROTOXIC COMPOUNDS: STREPTOMYCIN AND INDOMETHACIN. ANIMALS WERE TREATED ONCE WITH THE TEST COMPOUND BY THE APPROPRIATE ROUTE OF ADMINISTRATION AND GENOTOXIC EFFECTS WERE MEASURED AT THE TWO SAMPLING TIMES OF 3-6 AND 22-26H AFTER TREATMENT. REGARDING THE TISSUE PROCESSING, THE LIMITED BACKGROUND LEVEL OF DNA MIGRATION OBSERVED IN THE NEGATIVE CONTROL GROUPS THROUGHOUT ALL EXPERIMENTS DEMONSTRATED THAT THE ENZYMATIC ISOLATION METHOD IMPLEMENTED IN THE CURRENT STUDY IS APPROPRIATE. ON THE OTHER HAND, STREPTOZOTOCIN, 20MG/KG, USED AS POSITIVE REFERENCE CONTROL CONCURRENTLY TO EACH ASSAY, CAUSED A CLEAR INCREASE IN THE MEAN OLIVE TAIL MOMENT MEDIAN VALUE, WHICH ALLOWS VALIDATING THE CURRENT METHODOLOGY. UNDER THESE EXPERIMENTAL CONDITIONS, THE IN VIVO RODENT COMET ASSAY DEMONSTRATED GOOD SENSITIVITY AND GOOD SPECIFICITY: ALL THE FIVE RENAL GENOTOXIC CARCINOGENS WERE CLEARLY DETECTED IN AT LEAST ONE EXPRESSION PERIOD EITHER DIRECTLY OR INDIRECTLY, AS IN THE CASE OF CISPLATIN: FOR THIS CROSS-LINKING AGENT, THE SIGNIFICANT DECREASE IN DNA MIGRATION OBSERVED UNDER STANDARD ELECTROPHORESIS CONDITIONS WAS CLEARLY AMPLIFIED WHEN THE DURATION OF ELECTROPHORESIS WAS INCREASED UP TO 40MIN. IN CONTRAST, EPIGENETIC AND NEPHROTOXIC COMPOUNDS FAILED TO INDUCE ANY SIGNIFCANT INCREASE IN DNA MIGRATION. IN CONCLUSION, THE IN VIVO RODENT COMET ASSAY PERFORMED ON ISOLATED KIDNEY CELLS COULD BE USED AS A TOOL TO INVESTIGATE THE GENOTOXIC POTENTIAL OF A TEST COMPOUND IF NEOPLASIC/PRENEOPLASIC CHANGES OCCUR AFTER SUBCHRONIC OR CHRONIC TREATMENTS, IN ORDER TO DETERMINE THE ROLE OF GENOTOXICITY IN TUMOR INDUCTION. MOREOVER, THE EPIGENETIC CARCINOGENS AND CYTOTOXIC COMPOUNDS DISPLAYED CLEARLY NEGATIVE RESPONSES IN THIS STUDY. THESE RESULTS ALLOW EXCLUDING A DNA DIRECT-ACTING MECHANISM OF ACTION AND CAN THUS SUGGEST THAT A THRESHOLD EXISTS. THEREFORE, THE CURRENT IN VIVO RODENT COMET ASSAY COULD CONTRIBUTE TO ELUCIDATE AN EPIGENETIC MECHANISM AND THUS, TO UNDERTAKE A RISK ASSESSMENT ASSOCIATED WITH HUMAN USE, DEPENDING ON THE EXPOSURE LEVEL. 2007 17 1287 24 DECITABINE-INDUCED APOPTOSIS IS DERIVED BY PUMA AND NOXA INDUCTION IN CHRONIC MYELOID LEUKEMIA CELL LINE AS WELL AS IN PBL AND IS POTENTIATED BY SAHA. RESTORATION OF CELLULAR APOPTOTIC PATHWAYS PLAYS A CRUCIAL ROLE IN CANCER THERAPY STRATEGIES. IN A BROAD SPECTRUM OF ANTICANCER DRUGS, EPIGENETIC EFFECTORS ARE IN THE CENTER OF INTEREST MOSTLY BECAUSE OF POTENTIAL REVERSIBILITY OF THEIR ACTION. METHYLATION STATUS OF THE CELLS IS INFLUENCED BY METHYLTRANSFERASE INHIBITOR 2-DEOXY-5'-AZACYTIDINE (DECITABINE, DAC), BUT HIGHER CONCENTRATIONS OF THIS AGENT CAUSE A DNA-DAMAGE. IN OUR STUDY, TUMOR SUPRESSOR P53-APOPTOTIC PATHWAY WAS ACTIVATED IN DECITABINE-INDUCED CELL DEATH. EXPRESSION OF P53-INDUCIBLE BH3-ONLY APOPTOTIC PROTEINS PUMA AND NOXA WAS ELEVATED AND LARGE ACTIVATION OF EXECUTIVE CASPASES WAS OBSERVED. THE EXTENT OF ACETYLATION IN THE CELL IS AFFECTED BY HISTONEDEACETYLASE INHIBITOR SUBEROYLANILIDE HYDROXAMIC ACID (SAHA). COMBINATION OF SAHA WITH DECITABINE BROUGHT SYNERGISTIC EFFECT ON APOPTOSIS TRIGGERING IN CML-T1 CELL LINE, BUT APOPTOSIS AS WELL AS NECROSIS OCCURRED ALSO IN NORMAL PERIPHERAL BLOOD LYMPHOCYTES. THEREFORE, PROMISING POTENTIAL OF SUCH COMBINED THERAPY CALLS FOR MORE DETAILED INVESTIGATION OF UNWANTED EFFECTS IN NORMAL CELLS. 2011 18 2302 34 EPIGENETIC REGULATION OF CANCER STEM CELL MARKER CD133 BY TRANSFORMING GROWTH FACTOR-BETA. HEPATOCELLULAR CARCINOMA (HCC) IS THE THIRD LEADING CAUSE OF CANCER MORTALITY WORLDWIDE. CD133, A TRANSMEMBRANE GLYCOPROTEIN, IS AN IMPORTANT CELL SURFACE MARKER FOR BOTH STEM CELLS AND CANCER STEM CELLS IN VARIOUS TISSUES INCLUDING LIVER. CD133 EXPRESSION HAS BEEN RECENTLY LINKED TO POOR PROGNOSIS IN HCC PATIENTS. CD133+ LIVER CANCER CELLS ARE CHARACTERIZED BY RESISTANCE TO CHEMOTHERAPY, SELF-RENEWAL, MULTILINEAGE POTENTIAL, INCREASED COLONY FORMATION, AND IN VIVO CANCER INITIATION AT LIMITED DILUTION. RECENT STUDIES DEMONSTRATE THAT CD133 EXPRESSION IS REGULATED BY DNA METHYLATION. IN THIS STUDY, WE EXPLORED THE ROLE OF TRANSFORMING GROWTH FACTOR BETA (TGFBETA), A MULTIFUNCTIONAL CYTOKINE THAT PLAYS A CRITICAL ROLE IN CHRONIC LIVER INJURY, IN THE REGULATION OF CD133 EXPRESSION. TGFBETA1 IS CAPABLE OF UP-REGULATING CD133 EXPRESSION SPECIFICALLY WITHIN THE HUH7 HCC CELL LINE IN A TIME- AND DOSE-DEPENDENT MANNER. MOST IMPORTANT, TGFBETA1-INDUCED CD133+ HUH7 CELLS DEMONSTRATE INCREASED TUMOR INITIATION IN VIVO. FORCED EXPRESSION OF INHIBITORY SMADS, INCLUDING SMAD6 AND SMAD7, ATTENUATED TGFBETA1-INDUCED CD133 EXPRESSION. WITHIN CD133- HUH7 CELLS, TGFBETA1 STIMULATION INHIBITED THE EXPRESSION OF DNA METHYLTRANSFERASES (DNMT) 1 AND DNMT3BETA, WHICH ARE CRITICAL IN THE MAINTENANCE OF REGIONAL DNA METHYLATION, AND GLOBAL DNMT ACTIVITY IN CD133- HUH7 CELLS WAS INHIBITED BY TGFBETA1. DNMT3BETA INHIBITION BY TGFBETA1 WAS PARTIALLY RESCUED WITH OVEREXPRESSION OF INHIBITORY SMADS. LASTLY, TGFBETA1 TREATMENT LED TO SIGNIFICANT DEMETHYLATION IN CD133 PROMOTER-1 IN CD133- HUH7 CELLS. CONCLUSION: TGFBETA1 IS ABLE TO REGULATE CD133 EXPRESSION THROUGH INHIBITION OF DNMT1 AND DNMT3BETA EXPRESSION AND SUBSEQUENT DEMETHYLATION OF PROMOTER-1. TGFBETA1-INDUCED CD133+ HUH7 CELLS ARE TUMORIGENIC. THE MECHANISM BY WHICH TGFBETA INDUCES CD133 EXPRESSION IS PARTIALLY DEPENDENT ON THE SMADS PATHWAY. 2010 19 4821 42 OCHRATOXIN A: 13-WEEK ORAL TOXICITY AND CELL PROLIFERATION IN MALE F344/N RATS. OCHRATOXIN A (OTA) IS NEPHROTOXIC AND A POTENT RENAL CARCINOGEN. MALE RATS ARE MOST SUSCEPTIBLE TO OTA TOXICITY, AND CHRONIC ADMINISTRATION OF OTA (70 AND 210 MICROG/KG BW) FOR 2 YEARS HAS BEEN SHOWN TO INDUCE HIGH INCIDENCES OF ADENOMAS AND CARCINOMAS ARISING FROM THE STRAIGHT SEGMENT OF THE PROXIMAL TUBULE EPITHELIUM. IN CONTRAST, TREATMENT WITH A LOWER DOSE OF 21 MICROG/KG BW DID NOT RESULT IN INCREASED TUMOR RATES, SUGGESTING A NONLINEAR DOSE RESPONSE FOR RENAL TUMOR FORMATION BY OTA. SINCE THE MECHANISM OF OTA CARCINOGENICITY IS STILL LARGELY UNKNOWN, THIS STUDY WAS CONDUCTED TO INVESTIGATE EARLY FUNCTIONAL AND PATHOLOGICAL EFFECTS OF OTA AND TO DETERMINE IF SUSTAINED STIMULATION OF RENAL CELL PROLIFERATION PLAYS A ROLE. MALE F344/N RATS WERE TREATED WITH OTA FOR UP TO 13 WEEKS UNDER CONDITIONS OF THE NATIONAL TOXICOLOGY PROGRAM (NTP) BIOASSAY. CELL PROLIFERATION IN THE RENAL CORTEX AND OUTER STRIPE OF THE OUTER MEDULLA (OSOM) WAS DETERMINED USING BROMODEOXYURIDINE INCORPORATION AND IMMUNOHISTOCHEMISTRY. HISTOPATHOLOGICAL EXAMINATION SHOWED RENAL ALTERATIONS IN MID- AND HIGH-DOSE-TREATED ANIMALS INVOLVING SINGLE-CELL DEATH AND PROMINENT NUCLEAR ENLARGEMENT WITHIN THE STRAIGHT PROXIMAL TUBULES. TREATMENT WITH OTA AT DOSES OF 70 AND 210 MICROG/KG BW LED TO A MARKED DOSE- AND TIME-DEPENDENT INCREASE IN RENAL CELL PROLIFERATION, EXTENDING FROM THE MEDULLARY RAYS INTO THE OSOM. NO EFFECTS WERE EVIDENT IN KIDNEYS OF LOW-DOSE-TREATED ANIMALS OR IN THE LIVER, WHICH IS NOT A TARGET FOR OTA CARCINOGENICITY. A NO OBSERVED EFFECT LEVEL IN THIS STUDY WAS ESTABLISHED AT 21 MICROG/KG BW, CORRELATING WITH THE DOSE IN THE NTP 2-YEAR BIOASSAY THAT DID NOT PRODUCE RENAL TUMORS. THE APPARENT CORRELATION BETWEEN ENHANCED CELL TURNOVER AND TUMOR FORMATION INDUCED BY OTA INDICATES THAT STIMULATION OF CELL PROLIFERATION MAY PLAY AN IMPORTANT ROLE IN OTA CARCINOGENICITY AND PROVIDES FURTHER EVIDENCE FOR AN EPIGENETIC, THRESHOLDED MECHANISM. 2007 20 4819 32 OCCURRENCE OF TOXICITY AND CELL PROLIFERATION AFTER A SINGLE GAVAGE ADMINISTRATION OF CHLOROFORM TO MALE F344 RATS. CHLOROFORM, AN INDUSTRIAL SOLVENT AND ONE OF THE MOST COMMON ENVIRONMENTAL CONTAMINANTS WHICH PRODUCES CARCINOGENIC EFFECTS IN THE LIVER AND KIDNEY OF RODENTS, IS NOT GENOTOXIC IN MOST TRADITIONAL BACTERIAL AND MAMMALIAN TEST SYSTEMS. ITS CARCINOGENIC POTENTIAL APPEARS ATTRIBUTABLE TO THE SUSTAINED CELL TURNOVER (REGENERATIVE HYPERPLASIA) WHICH RESULTS FROM CHRONIC CHLOROFORM TOXICITY. IN THIS PRESENT STUDY, CELL PROLIFERATION (REPLICATIVE DNA SYNTHESIS, RDS) AND HISTOPATHOLOGICAL CHANGES IN HEPATOCYTES AND RENAL TUBULAR EPITHELIAL CELLS WERE ASSESSED IN MALE F344 RATS FOLLOWING A SINGLE GAVAGE CHLOROFORM EXPOSURE (50, 150 OR 500 MG/KG). IN ADDITION, BIOCHEMICAL PARAMETERS (BUN, GOT, LDH AND NAG) WERE EXAMINED USING PLASMA AND URINE SAMPLES. CELL PROLIFERATION AND HISTOPATHOLOGICAL CHANGES (E.G. HYPERTROPHY, NECROSIS, VACUOLATION) WERE ONLY SEEN AT THE DOSE OF 500 MG/KG IN THE LIVER AND KIDNEY. AT THE SAME DOSE, ALL BIOCHEMICAL MARKERS WERE INCREASED AT THE 24 TO 48 HR TIME POINTS. THESE RESULTS OBTAINED ARE THUS IN LINE WITH EARLIER FINDINGS POINTING TO EPIGENETIC CARCINOGENICITY. 1998